drugset / Trial / NCT03680261

Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. Chemoradiotherapy

NCT03680261

Phase 3 Unknown 556 enrolled Shanghai Zhongshan Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This Enriched-CRT 2017 trial is a prospective, multicenter trial for adjuvant chemoradiotherapy (CRT) and chemotherapy (CT) in radical resected advanced gastric cancer (GC) patients with lymph node metastasis (LN+) and lymphovascular Invasion (LVI+). The primary purpose of this study is to evaluate the 3-year overall survival (OS) of enrolled patients receiving adjuvant chemoradiotherapy compared with those receiving adjuvant chemotherapy. The second purpose is to evaluate 3-year disease free survival (DFS) and determine the safety of CRT compared with CT in the patients enrolled in this study.

Timeline

Start
2018-10-01
Primary completion
2023-09-30
Completion
2023-09-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule
Subject Oxaliplatin Small molecule
Subject S-1 Small molecule

Indications